The Board of AnteoTech Ltd. commenced a search for a successor to the current chair, Dr. Jack Hamilton, who has advised the company of his intention to retire from the board. The Board also announced that Mr. Christopher Parker will become an Executive Director with immediate effect to assist management with delivery of the Company's near-term plans and objectives. Mr. Parker was a previous CEO for AnteoTech between April 2018 and May 2019 and then an Executive Director until November 2019 when he was appointed as a Non-Executive Director.

Mr. Parker has 30 years plus of experience in both domestic and international life sciences sector predominantly with Roche Diagnostics ("Roche"), an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in late 2017, he was Managing Director for UK & Ireland and Management Centre for European Agents where he had responsibility for all diagnostic products in the Roche portfolio. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets.